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ABSTRACT
Although 5-year survival rate of non-metastatic colorectal cancer (CRC) is 
high, about 10% of patients in stage I and II still develop into metastatic CRC and 
eventually die after resection. Currently, there is no effective biomarker for predicting 
the prognosis of non-metastatic CRC in clinical practice. In this study, we identified 
miR-650 as a biomarker for prognosis prediction. We observed that the expression 
of miR-650 in tumor tissues had a positive association with overall survival. MiR-650 
inhibited cell growth and invasion in vitro and in vivo. Furthermore, miR-650 targeted 
AKT2 and repressed the activation of the AKT pathway (AKT2/GSK3β/E-cadherin). Thus 
it induced the translocation of E-cadherin and β-catenin in cancer cells. Our results 
highlight the potential of miR-650 as a prognostic prediction biomarker and therapeutic 
target in non-metastatic CRC via inhibition of the AKT2/GSK3β/E-cadherin pathway.
INTRODUCTION
Colorectal cancer (CRC) is one of the leading 
causes of cancer mortality worldwide. About 10 percent 
of CRC patients in stage I and II develop tumor metastasis 
and eventually die within 5 years after resection [1]. 
Therefore, identifying high-risk early-stage (stage I and 
II) CRC patients for aggressive chemotherapy is critical 
to improving patient outcome and avoiding unnecessary 
chemotoxicity. The current tools to assess CRC prognosis 
include the AJCC TNM staging system, other clinical and 
pathological variables such as obstruction, perforation, 
lymph vascular invasion, aneuploidy and molecular 
markers such as loss of heterozygosity (LOH) of 18q 
or the presence of microsatellite stable tumors, K-ras 
mutation, stromal matrix metalloproteinase-2 expression, 
group IIA phospholipase A2, 5q retention and tumor 
stroma ratio [2–8]. The clinical significance of these 
markers is incompletely understood, and many are either 
limited to a small portion of the patient population or 
exhibit unsatisfactory assay performance. Therefore, it is 
critical to either identify newer predictive and prognostic 
markers or to discover new target for treatment of high-
risk early-stage CRC patients.
MicroRNAs (miRNAs) are small noncoding 
RNAs which repress gene expressions by recognizing 
complementary target sites in the 3′-UTRs of mRNAs 
[9]. MiRNAs, having strong associations with clinical 
outcomes of cancer [10, 11], have become major potential 
prognostic biomarkers for cancer patients. For example, 
miR-320 and miR-498 are identified to be predictive 
biomarkers for high-risk stage-II colon cancer patients [12]. 
MiR-21 expression appears to identify high-risk stage-II 
colon cancer patients as well [13–16]. However, miR-21 
can be detected in both tumor cells and tumor stroma cells, 
and its function in CRC remains unclear. Therefore, it is 
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still questionable whether miR-21 qualifies as a therapy 
target. Although some studies on miRNA expression of 
CRC prognosis have been reported [17–19], the majority 
of these studies used the whole tumor tissues as study 
material. Analyses of such complex tissues could conceal 
the specific signature of the truly transformed cancerous 
cells [20]. In order to discover reliable biomarkers, we 
macrodissected the tumor tissues and made sure that at 
least 75 percent of the samples were cancer cells. 
MiR-650 plays different roles in several types of 
cancer. Mraz et al. have reported that higher expression 
of miR-650 is associated with a favorable prognosis in 
chronic lymphocytic leukemia (CLL) [21]. On the other 
hand, some reports have shown that miR-650 could 
stimulate metastasis in gastric cancer [22] and promote 
hepatocellular carcinoma [23]. The inconsistent reports 
suggest that miR-650 plays different roles in different 
cancers or in the different stages of a single cancer. 
Although the expression correlation between miR-650 
and NDRG2 (a target gene) in CRC has been reported, the 
function and downstream pathway of miR-650 in CRC are 
still unclear [24]. Furthermore, the relationship between 
the expression profile of miR-650 and prognosis of non-
metastatic CRC is also unclear.
In this study, we discovered that the expression 
of miR-650 in CRC tumor tissues had a strong positive 
association with overall survival (OS) of non-metastatic 
CRC patients. Our data indicated that miR-650 inhibited 
CRC cells in vitro and in vivo by repressing the AKT2 
pathway. MiR-650 had considerable clinical value in the 
prognosis prediction of non-metastatic CRC and potential 
target therapy in early-stage CRC.
RESULTS
MiR-650 expression has a positive association 
with the prognosis of early-stage CRC 
The clinical, histopathological, and survival details 
of the 96 cases were summarized in Table 1. MiRNA 
microarray was used to measure the expression of human 
miRNAs in tumor cells derived from 8 formalin-fixed, 
paraffin-embedded (FFPE) samples among early-stage 
CRC patients. Comparison of patients with poor prognosis 
to those with good prognosis revealed three under-
expressed miRNAs (Fold change < 0.5, P <= 0.05) and two 
over-expressed miRNAs (Fold change > 2, P < 0.05) (GEO 
accession number GSE79810, Supplementary Table 1). 
Among those miRNAs, miR-650 was under-expressed 
(Fold change 0.3, P = 0.05). This result was further 
validated using reverse-transcriptase-polymerase-chain-
reaction (qRT-PCR) analysis on a total of 96 early-stage 
CRC samples. MiR-650 was significantly under-expressed 
in 44 patients with poor prognosis as compared with 
52 patients with good prognosis (Fold change 0.13, 
P < 0.01) (Figure 1A). From the ROC analysis, miR-650 
expression <= 0.2382 was considered relatively lower 
expression and > 0.2382 was considered relatively 
higher expression (AUC = 0.745). To further clarify the 
association between miR-650 expression and OS with 
different stages of tumor pathology in non-metastatic 
CRC, we performed survival analysis. As shown in 
Figure 1B, patients with a relatively lower expression of 
miR-650 had shorter OS than those with a relatively higher 
expression, even at different T stages (T2, T3 and T4): 
significantly positive associations were detected at T3 and 
T4 (T3: hazard ratio [HR] = 6.68, 95% CI: 2.55–17.52, 
P < 0.01; T4: HR = 3.48, 95% CI: 1.06–11.44, P < 0.05), 
respectively. The similar association pattern was observed 
at T2 (HR = 4.54, 95% CI: 0.44–46.48, P > 0.05). We 
conclude that miR-650 has the potential to be a prognostic 
predictive biomarker in non-metastatic CRC.
MiR-650 inhibits cell proliferation in vitro and 
in vivo
The significant under-expression of miR-650 in 
the poor prognosis group led us to explore the biological 
functions of miR-650 in colon cancer cells. We also found 
expression of miR-650 was significantly decreased in 
carcinomas compared to normal tissues in our previous 
study [25]. We tested the basal expression levels of miR-
650 in seven colon cancer cell lines (Supplementary 
Figure 1A). DLD-1 cells showed a relatively lower 
expression level of miR-650 compared with other cells, 
while HCT-8 showed a moderate expression level of 
miR-650. The miR-650 precursor was stably transfected 
to DLD-1 and HCT-8 cells with lentiviral vectors, and 
miR-650 expression was increased 5.0 fold in DLD-1 
transfectants and 3.2 fold in HCT-8 transfectants 
compared with NC controls (transfected with scrambled 
control  sequence) (Supplementary Figure 1B). As 
illustrated in Figure 2, miR-650 significantly inhibited cell 
growth in both DLD-1 (21.0 ± 9.7% reduction at 96 h, 
P < 0.05, Figure 2A) and HCT-8 cell lines (9.9 ± 2.4% 
reduction at 72 h, P < 0.05, Figure 2B). These data 
indicated a growth inhibitory role of miR-650 in vitro. 
In vivo experiment with DLD-1 cell line in the 
subcutaneous tumor mice model showed that the tumor 
volumes were 0.87 ± 0.22 cm3 in the NC control and 
0.57 ± 0.29 cm3 in the miR-650 transfectant group, 
respectively (P = 0.05, Figure 2C, 2D). Meanwhile, 
Ki-67 expression in miR-650 group showed a lower score 
compared with the NC group in tumor xenograft mice (Fold 
change 0.64, P = 0.09, Supplementary Figure 2). These data 
indicated that miR-650 could inhibit tumor growth in vivo.
MiR-650 inhibits cell migration and invasion  
in vitro and in vivo
The potential impact of miR-650 on cell migration 
and invasion were assessed by transwell assays. 
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MiR-650 transfectants had significantly reduced migration 
and invasion rates compared with NC controls in both 
DLD-1 and HCT-8 cells (Figure 3A, 3B). The migratory 
abilities were inhibited by miR-650 compared with 
NC controls in DLD-1 cells (60.4 ± 23.0% reduction, 
P < 0.05) and in HCT-8 cells (73.4 ± 15.3% reduction, 
P < 0.05) (Figure 3A, Supplementary Figure 3A). The 
invasive abilities were inhibited by miR-650 compared 
with NC controls in DLD-1 cells (60.0 ± 14.2% reduction, 
P < 0.05) and in HCT-8 cells (81.6 ± 6.9% reduction, 
P < 0.05) (Figure 3B, Supplementary Figure 3B). 
We planted tumor tissues from the two groups of 
subcutaneous tumor models on colon serosa of tumor 
xenograft mice. We observed that cancer cells invaded 
from serous to colon epithelial tissue in the animals 
from the NC group (Figure 3C), while cancer cells 
only invaded from serous to colon submucosa tissue 
in the animals from the miR-650 group (Figure 3D). 
Meanwhile, tumor thrombi were found in 6 out of 
8 mice in the NC group but were only found in 3 out of 
7 mice in the miR-650 group (Figure 3E). Furthermore, 
according to the VM identification in the xenograft 
model, fewer VM channels (1.27 ± 0.30) were found in 
the miR-650 group than in the NC group (1.63 ± 0.21) 
(P < 0.05) (Figure 3F, Table 2, Supplementary Figure 4). 
Therefore, we confirmed that miR-650 might inhibit the 
tumor invasion by blocking the blood supply of tumor 
cells in CRC.
Table 1: Characteristics of patients and tumors in the study
Microarrays qRT-PCR (including samples from discovery and validation phases)
Characteristic Good Prognosisa Poor Prognosisb Good Prognosisa Poor Prognosisb
Number of Cases 4 4 52 44
Gender
Male 2 1 23 19
Female 2 3 29 25
Age at Diagnosis
Median 67 73 67 70
Min 57 67 47 50
Max 78 81 89 91
Survival Time (months)
Median 72.3 28.8 75.9 30.7
Min 61 17 60 0.2
Max 84 51 87 58
TNM Stage of Diseasesc
Tumour (T) Stage                                              
T1 0 0 0 0
T2 1 0 19 4
T3 3 4 24 27
T4 0 0 9 13
Nodal (N) Status 0 0 0 0
Distant Metastases(M) 0 0 0 0
Location of CRC
Left 1 1 3 5
Right 2 1 16 12
Rectum and Sigmoid 1 2 31 23
Transverse 0 0 1 3
Unknown 0 0 1 1
aPatients with good prognosis were all alive more than 5 years after surgery.
bPatients with poor prognosis were all died of CRC recurrence within 5 years after surgery.
cAll the patients observed had no metastasis at the time of diagnosis and did not have chemotherapy.
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MiR-650 targets to AKT2 and represses AKT 
pathway
To understand the underlying mechanisms that are 
implicated in the impact of miR-650 on the prognosis of 
early-stage CRC, potential target genes were searched 
using miRecords and examined using the KEGG database. 
AKT2 was predicted as a candidate target gene of miR-650. 
AKT2 has four seed sequences that may combine 
with miR-650 (Supplementary Table 2). To identify the 
miR-650 binding site on AKT2, we performed a series of 
luciferase assays. The luciferase activity of the vector with 
the combination of the 1st and 2nd seed sequence was 
significantly reduced to 58.1 ± 9.7% in cells transfected 
with miR-650 precursor compared with negative control 
cells (P < 0.05). There were no significant luciferase 
Figure 1: MiR-650 is positively associated with the prognosis of early-stage CRC. (A) MiR-650 expression in carcinoma 
cells among 96 non-metastasis CRC patients with different prognosis on qRT-PCR. (B) Survival analysis in different tumor stages of non-
metastasis CRC patients. 
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activity changes of vectors with the 3rd or 4th seeds 
(Figure 4A). In addition, the mutation experiment showed 
that the reduction of luciferase activities disappeared when 
the 1st seed sequence was mutated, but this phenomenon 
was not observed when the 2nd seed sequence was 
mutated (Figure 4A). This observation indicated that the 
binding site of miR-650 was located at the 1st seed.
Furthermore, the activation of AKT pathway 
was also investigated after the miR-650 precursor was 
transfected in DLD-1 and HCT-8 cells. As shown in 
Figure 4B and 4C, the protein levels of AKT2 were 
decreased by 37.3 ± 12.7% (P < 0.05) and 45.9 ± 14.6% 
(P < 0.05) in DLD-1 and HCT-8 cells, respectively. 
The expression levels of phosphorylated AKT (p-AKT, 
Ser473) were decreased by 53.6 ± 5.6% (P < 0.05) and 
42.0 ± 12.1% (P < 0.05), respectively,  while p-GSK3β 
(Ser9) levels were decreased by 58.4 ± 12.0% (P < 0.05) 
and 15.2 ± 1.9% (P < 0.05), respectively. Nevertheless, 
there were no significant changes in GSK3β expression 
levels after transfection in both two cell lines (P > 0.05, 
Figure 4B, 4C). E-cadherin is a main component of cell-
cell adhesion junctions. Suppression or mislocalization of 
E-cadherin from the cell membrane was observed in CRC 
patients [26]. Interestingly, although the total expression 
level of E-cadherin had no significant difference after 
transfection of the miR-650 precursor in DLD-1 and HCT-
8 cells (P > 0.05, Figure 4B, 4C), dramatically increased 
E-cadherin expression levels were observed on the cell 
surfaces in miR-650 stable transfectants (Figure 4D, 
Supplementary Figure 5). E-cadherin sequestered 
β-catenin to cell surfaces and the translocation of β-catenin 
to nucleus activated the Wnt/β-catenin pathway [27]. We 
observed that β-catenin on the cell membrane increased 
in DLD-1 miR-650 stable transfectants (Supplementary 




Mean ± SD P. Value
1 2 3 4 5 6 7
MiR-NC 1.6 1.8 1.2 1.8 1.8 1.6 1.6 1.63 ± 0.21
0.026
MiR-650 1.2 1.2 1.2 1.6 1.5 0.7 1.5 1.27 ± 0.30
aMean of every ten 400× fields per mouse model.
Figure 2: MiR-650 inhibits cell growth in vitro and in vivo. (A) MiR-650 inhibited cell growth on 72 h and 96 h in DLD-1 
(**P = 0.07, *P < 0.05). (B) MiR-650 significantly inhibited cell growth on 72 h in HCT-8 (*P < 0.05). (C) MiR-650 had a growth 
inhibitory effect in vivo during 3 weeks in subcutaneous tumor mice model (*P = 0.05). (D) In subcutaneous tumor mice model, the volume 
of tumors in NC group was larger than that of tumors in miR-650 group.
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Figure 6). β-catenin levels in the nucleus were also 
decreased by 22.8 ± 2.1% (P < 0.05) and 27.5 ± 3.0% 
(P < 0.05) when transfected with miR-650 precursor in 
DLD-1 and HCT-8 cells  (Figure 4B, 4C).
AKT2 overexpression restores cell migratory/
invasive abilities and proliferation inhibited by 
miR-650
When we transfected pcDNA3.1-AKT2 into 
DLD-1 and HCT-8 cells, which had been stably transfected with 
miR-650, cell migratory and invasive abilities were again 
assessed by transwell assays. As expected, miR-650 was able to 
reduce the migration/invasion rates significantly compared with 
NC controls when both cell lines were only transfected with 
pcDNA3.1 plasmids. However, when miR-650 transfectants 
were transfected with a pcDNA3.1-AKT2 plasmid, migratory 
abilities of cells were increased back to 210.5 ± 62.9% 
(P < 0.05) in DLD-1 and 166.60 ± 46.1% (P = 0.09) in 
HCT-8, respectively, as compared with that of cells transfected 
with pcDNA3.1 only (Figure 5A, 5B). The invasive abilities 
of cells were increased back to 172.86 ± 35.0% (P < 0.05) in 
DLD-1 and 179.6 ± 25.5% (P = 0.05) in HCT-8, respectively, 
compared with controls (Figure 5A, 5C). Futhermore, cell 
proliferation inhibited by miR-650 could be restored by AKT2 
overexpression in DLD-1 cells (P < 0.05, Figure 5D).
Low-expression of miR-650 in CRC cells 
promotes cancer via AKT2/ GSK3β/ E-cadherin 
pathway
Our results indicated that miR-650 directly targeted 
the 3′-UTR of AKT2 , repressed the expression of AKT2, 
and then inhibited the activation of the AKT2 pathway. 
Otherwise, in the relatively lower miR-650 expression 
CRC tumor cells, the inhibition of AKT2 pathway 
activation is revived. In this situation, AKT2 and its 
down streams, such as GSK3β, are over-phosphorylated, 
which promote the nuclear translocation of β-catenin. 
The expression of E-cadherin on CRC cell membranes is 
decreased without the combination of β-catenin. Thus, the 
cell-cell adhesions between carcinoma cells are weakened 
and the abilities of migration and invasion of carcinoma 
cells increase (Figure 6). Therefore, the patients with low 
expression of miR-650 will have poor prognosis.
DISCUSSION
Although early-stage (stage I and II) CRC patients 
have comparatively good prognosis, some of them die of 
recurrence or metastases after surgical resection. These 
patients could not be accurately identified by the available 
pathological/clinical staging or molecular measures. 
Figure 3: MiR-650 inhibits cell migratory and invasive abilities. (A) Cell migratory abilities in DLD-1 and HCT-8 cells. *P < 0.05 
vs. NC group. (B) Cell invasive abilities in DLD-1 and HCT-8 cells. *P < 0.05 vs. NC group. (C) Representative figure of NC group. Cancer 
cells invaded from colon serous to epithelial tissue (HE 100×). (D) Representative figure of miR-650 group. Cancer cells invaded from 
colon serous to submucosa tissue (▲HE 100×). (E) Representative figure of tumor cell embolus in xenograft mice model (thick arrow, HE 
100×). (F) Representative VM channels in xenograft mice model. The endothelium-independent vessels (VM) (blue arrows) were lined by 
tumor cells, and PAS-positive substances enclosed the tumor cells to form the basement membrane-like structure. However, the endothelium 
marker CD34 was negative. The endothelium-dependent vessels (yellow arrows) were CD34 positive, and PAS positive (400×).
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Predictive and prognostic biomarkers are needed to help 
clinicians to identify the high-risk patients and to treat 
them accordingly. In addition, those biomarkers also could 
be potential therapeutic targets. 
In this study, we report that miR-650 expression 
in CRC cells is positively correlated with patient OS in 
non-metastatic early-stage CRC. Furthermore, miR-650 
can identify high-risk patients, even at the same tumor 
stage (T3 or T4 stage), 18 months later after resection. 
Although there is no statistical significance at the T2 
stage, the similar pattern was still observed. Due to the 
lack of availability of T1 stage CRCs in this study, such 
association was not evaluated. Compared with the T2 
stage, the tumor at the T3 stage has broken the barrier of 
muscularis propria and grown into the outermost layer of 
the colon or rectum. To understand if miR-650 expression 
is able to predict the progression of T2 or even T1, further 
validations will be needed. 
Our results indicate that miR-650 could be a strong 
candidate as a prognostic biomarker in early-stage CRC. In 
addition, we have measured miR-650 expression profiles 
in epithelial cells derived from snap-frozen colorectal 
surgical tissues by microarray in a previous study [25]. As 
shown in Supplementary Table 3, miR-650 expression is 
significantly decreased in carcinoma compared to normal 
tissues (P < 0.05). These data suggest that miR-650 plays 
Figure 4: MiR-650 targets to AKT2. *P < 0.05 vs. NC control. (A) Luciferase assays. ING4 was used as a positive control. (B–C) Western 
blot examined AKT2, p-AKT, GSK3β, p-GSK3β, E-cadherin of total protein and β-catenin of nuclear protein. (D) Immunofluorescence of 
E-cadherin was increased on cell surface in DLD-1 cells and HCT-8 cells by miR-650 (400×).
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a role as a tumor suppressor gene in CRC progression. 
Interestingly, miR-650 expression in the left colon is 
lower than in the rectum and sigmoid in CRC (P < 0.05). 
However, there is no significant difference between left 
colon and right colon (P > 0.05) (Table 1, Supplementary 
Figure 7). To describe the relationship with miR-650 and 
CRC location, larger sample power is needed.  
 We demonstrated that miR-650 could inhibit AKT2 
activation and inhibit cell migration and invasion by 
restoring E-cadherin junctions. AKT2 is overexpressed in 
metastatic CRC, and suppression of AKT2 could inhibit 
metastatic ability in CRC cells [28]. We observed that 
miR-650 could directly bind to the 3′-UTR of AKT2 and 
repress its protein level. This result suggests that AKT2 
overexpression in non-metastatic CRC is caused by the 
loss of miR-650 in CRC cells. With low expression of 
miR-650 in CRC cells, AKT2 is over-activated, and 
GSK3β is over-phosphorylated. This promotes the nuclear 
translocation of β-catenin and the expression of E-cadherin 
on the cell membrane. This is the reason why epithelial 
Figure 5: AKT2 overexpression restores cell migratory/invasive abilities and proliferation. (A–C) AKT2 overexpression 
restored cell migratory and invasive abilities which were inhibited by miR-650 in DLD-1 and HCT-8 cells (200×). *P < 0.05. (D) AKT2 
overexpression restored cell proliferation inhibited by miR-650 in DLD-1 cells. *P < 0.05.
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cells with lower expression of miR-650 have fewer cell-
cell junctions and are more likely to gain the ability 
of migration and invasion. Therefore, there is a great 
possibility that these patients who had lower expression 
of miR-650 in cancer cells experienced shorter OS, even if 
they did not have metastasis at the time of first diagnosis.
Furthermore, our data demonstrated that miR-650 
would not only be a predictive biomarker but also be a 
potential drug target. MiR-650 can negatively regulate 
cell growth, migration and invasion potential of CRC cells 
in vitro and in vivo. Over-expression of AKT2 can restore 
the cell migratory and invasive abilities inhibited by 
miR-650. The AKT pathway triggers a number of signals 
in cancer development, making its components attractive 
drug targets in cancer therapy [29]. For example, the 
AKT inhibitor MK2206, used in treating metastatic CRC 
patients, is currently in phase II study [30]. The phase I/II 
study of Nelfinavir, an AKT signaling inhibitor, in patients 
with locally advanced rectal cancer has been completed 
[31]. Our data indicate that the expression of miR-650 
is very likely to be a guide of chemotherapy. A non-
metastatic CRC patient with relatively higher expression 
miR-650 will have good prognosis and no need to accept 
further chemotherapy after surgery. However, a non-
metastatic CRC patient with relatively lower expression 
miR-650 possibly has a bad prognosis and needs further 
chemotherapy after surgery, e.g. an AKT2 inhibitor.
In conclusion, we have identified that miR-650 has a 
positive correlation with OS in non-metastatic CRC. MiR-
650 could be a potential prognostic biomarker in high-risk 
non-metastatic CRC patients. Our data also suggest that 
miR-650 can inhibit CRC progression towards AKT2/
GSK3β/E-cadherin pathway, and finally influence patient 
prognosis. Therefore, miR-650 will likely be a potential 
therapeutic target in high-risk non-metastatic CRC.
MATERIALS AND METHODS
Clinical specimens
The study was approved by the local institutional 
review boards and written informed consent was obtained 
from all the 96 patients. The Reporting Recommendation 
for Tumor Marker (REMARK) guidelines were used to 
report the study [32]. Routine histological classification 
according to the WHO Classification of Tumors [33] 
was used for selection of study samples. All the lesions 
were diagnosed by two pathologists and independently 
reviewed by an expert CRC pathologist. Individuals 
with known inherited syndromes and patients who had 
received preoperative radiotherapy or chemotherapy were 
excluded. The prognosis information of patients was taken 
from Shanghai Municipal Center for Disease Control and 
Prevention, and telephone follow-ups. The follow-up time 
ended at the time of the patient’s death. Alternatively, 
follow-up time lasted until the time of this study for good 
prognosis patients who had survived. Patients who had 
lived for more than 5 years after surgery were classified as 
good prognosis, and patients who had died within 5 years 
from surgery were classified as poor prognosis. All the 
non-metastasis CRC patients with bad prognosis, who had 
full survival data from Fudan University Shanghai Cancer 
Center between 2000–2008, were included in this study. 
Patients with good prognosis were gender and age matched.
In the discovery phase, we used 8 FFPE CRC tissues 
(4 good prognoses and 4 poor prognoses) from Fudan 
University Shanghai Cancer Center in 2005. Tumor tissues 
were macrodissected under the light microscope with the 
control of hematoxylin-eosin (HE) staining slides. We 
made sure that at least 75 percent of the cells in the sample 
were cancerous [25]. In the validation phase, we used a 
Figure 6: Hypothesis of miR-650 inhibits AKT2/GSK3β/E-cadherin pathway in colorectal cancer cells. Green: under-
expressed. Magenta: over-expressed.
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total of 96 FFPE surgical tissue samples. Tumor tissues 
were also macrodissected. Figure 7A described the phases 
of this study design. 
Microarray hybridization
A total of 8 samples in the discovery phase were sent 
to Shanghai Biotechnology Corporation, for microarray 
analysis by Agilent human miRNA (8*15K) V12. Briefly, 
100 ng of total RNA was labelled with Cy3. Microarray 
slides were scanned by XDR Scan (PMT100, PMT5). The 
labelling and hybridization were performed according to 
protocols in the Agilent microRNA microarray system. 
Microarray image information was converted into spot 
intensity values using Feature Extraction Software 10.7 
(Agilent Technologies). Signal data after background 
subtraction was exported directly into the Gene Spring 
Software 11.0 (Agilent Technologies) for quantile 
normalization.
Total RNA extraction and quantitative RT-PCR
Total RNA was extracted using RecoverAll™ 
Total Nucleic Acid Isolation Kit (Ambion, Austin, TX). 
RNA concentrations were quantified by NanoDrop 1000 
Spectrophotometer (NanoDrop Technologies, Waltham, 
MA). MiR-650 expression level was measured by 
qRT-PCR using Taqman MicroRNA Assays (Applied 
Biosystems) on a total of 96 FFPE samples (including 
samples from discovery and validation phases). The 
expression level of U47 small nuclear RNA was used 
as an endogenous control. As per MIQE guidelines 
(PubMed ID 19246619), instead of ‘Ct’, the term ‘Cq’ (for 
quantification cycle) was used. 
Cell culture, lentiviral transduction and miRNA 
presursor transfection
Colon cancer cell lines (DLD-1 and HCT-8) and 
HEK293T were purchased from Shanghai Institute of Cell 
Biology, Chinese Academy of Sciences (Shanghai, China) 
and validated by STR profiling by Beijing Microread 
Genetics Corporation. Cells were grown in RPMI 1640 
medium (DLD-1 and HCT-8), DMEM (HEK293T) 
supplemented with 10% fetal bovine serum. Lentiviral 
vector was used to transfect miR-650 precursor sequence 
(miR-650 transfectant ) or scrambled control sequence 
(negative control) to DLD-1 and HCT-8 cells. HCT-8 
and DLD-1 cells were transfected with pre-miR-650 and 
paralleled negative control (Life technologies, Carlsbad, 
CA) respectively using Lipofectamine 2000 transfection 
reagent (Life technologies, Carlsbad, CA). 
Cell proliferation, migration and invasion assay
DLD-1 and HCT-8 cells (about 7000 cells per well) 
of miR-650 transfectants or negative controls (NC) were 
seeded in 96-well plates. Cell number was measured 
by Cell Counting Kit-8 (Dojindo) on different times 
(0, 24, 48, 72, 96 h). Cell migration and invasion ability 
were performed using transwell insert (8 μm, Corning). 
Cells were added to the upper chamber in RPMI 1640 
medium supplemented with 1% fetal bovine serum. 
Medium containing 20% serum was placed in the lower 
chamber. For the invasion assay, inserts were pre-coated 
with extracellular matrigel (BD Biosciences). Penetrated 
cells were stained with 0.1% crystal violet and counted. 
Tumor mice model
The animal experiments were approved by our 
institutional ethical board and reported according to the 
ARRIVE guidelines [34]. Nude BALB/c mice (SLRC 
Laboratory Animal) weighing approximate 20 g, male, 
6–8 weeks of age, were used. Animals were maintained 
in a laminar flow cabinet under specific-pathogen-free 
(SPF) conditions, kept at 26–28°C, humidity 40–60%. 
3–4 mice were housed in one cage, and were fed twice 
per day, with the cycle of 10 hours of day light and a 14 
hour night. Figure 7B described the study design. Firstly, 
4 × 106 DLD-1 cells of miR-650 transfectants or NC 
controls were subcutaneously (s.c.) injected into nude 
BALB/c mice (7 mice per group). Tumor size was 
measured at regular intervals twice per week, and the 
tumor volume was calculated using the formula: volume 
= 1/2 × (length × width2).  After three weeks, tumors were 
aseptically dissected.  In the next phase, to conduct a 
xenograft mice model, 16 nude BALB/c mice were divided 
into two groups (8 mice per group). Mice were anesthetized 
and sections of tumor tissues (1–2 mm3) of subcutaneous 
tumor model were planted on the serosa of the ileocecus. 
After surgery, the mice were injected subcutaneously with 
penicillin to prevent infection, once a day, for 3 days. The 
tumor xenograft mice were sacrificed four weeks after the 
surgery (one mouse died of intestinal obstruction three 
weeks after the surgery in the NC group). Tumor tissues 
were used for HE staining and immunohistological staining 
(IHC) for CD34 (2150–1, 1:200, Epitomics), Ki-67 
(16667, 1:100, Abcam). Vasculogenic mimicry (VM) in 14 
tissue samples derived from the mouse xenograft model 
were identified by CD34/PAS (periodic acid-schiff) dual-
staining. The channels which enclosed by tumor cells and 
PAS (+) / CD34 (−) were defined as VM [35]. 
Target prediction
Targets of miR-650 were predicted by miRecords 
(http://c1.accurascience.com/miRecords/). To increase the 
accuracy of prediction, the genes predicted by at least 4 of 
11 databases (DIANAmicroT, Microinspector, miRanda, 
MirTarget2, miTarget, NBmiRTar, PicTar, PITA, RNA22, 
RNAhybrid and TargetScan) were selected as candidate 
targets. The KEGG database (http://www.kegg.jp/kegg/
Oncotarget49544www.impactjournals.com/oncotarget
download/kegtools.html) was used to map the predicted 
targets to pathways.
Cloning and construction of AKT2 and related 
plasmids
The three nucleotides harboring four seed sequences 
in the 3′-UTR of AKT2 or two mutated seed nucleotides 
(Supplementary Table 4) were generated by Jieli Biology 
(Shanghai, China). They were cloned into pmirGLO 
vector. Full length cDNA of AKT2 was generated from 
HEK293T cells, and cloned into pcDNA3.1 vector. All the 
resulting constructs were confirmed by DNA sequencing. 
Luciferase activity assay
HEK293T cells were cotransfected with 40 nM 
miR-650 precursor or negative control (Ambion) and 
50 ng pmirGLO (Promega) constructs harboring the 
seed sequences of 3′-UTR of AKT2. The seed sequences 
were mutated in mutated reporter constructs. Cells were 
collected 48 hours after transfection and analyzed with 
Figure 7: Study design of this study. (A) Biomarker discovery and validation. (B) Tumor modelling in mice.
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a Dual-Luciferase Reporter Assay (Promega). Firefly 
luciferase activity was normalized to Renilla luciferase 
activity accordingly. ING4 was reported to be a miR-650 
target [22] and was selected as a positive control.
Western blot analysis
Total protein and nuclear protein were harvested 
48 hours after transfection (NE-PER Nuclear and 
Cytoplasmic Extraction Reagents). The protein expression 
of following antibodies were detected: AKT2 (sc-5270, 
1:500, Santa Cruz Biotechnology), p-AKT (Ser473, 
1:1000, no. 9271, Cell Signaling Technology), GSK3β 
(sc-9166, 1:1000, Santa Cruz Biotechnology),  p-GSK3β 
(Ser9, 1:1000, no. 9336, Cell Signaling Technology), 
E-cadherin (24E10, 1:1000, no. 3195, Cell Signaling 
Technology), and β-catenin (D10A8, 1:1000, no. 8480, 
Cell Signaling Technology). The expression level of 
GAPDH (sc-166574, 1:1000, Santa Cruz Biotechnology) 
and TBP (2H3B2, 1:5000, protein tech) were used as 
endogenous controls.
Immunofluorescence
1 × 104 DLD-1 and HCT-8 cells of miR-650 
transfectants or NC controls were seeded into 24-well 
plate. After being blocked with 10% goat serum for half an 
hour, cells were incubated with anti-E-cadherin antibody 
(1:400, Abcam) for 1 hour. Followed by incubation with 
Cy3-conjugated secondary antibody (1:500, proteintech) 
for 1 hour, cells were stained by DAPI and observed under 
confocal microscope (Leica, Microsystems). 
Statistical analysis
Unpaired t-test with Benjaminie-Hochberg 
correction was used for differentially expressed 
microRNAs in 8 samples in discovery phase. Receiver 
operating characteristic (ROC) curve analysis [36] was 
performed to determine the specificity and sensitivity of 
miR-650 as predicted biomarker in a total of 96 samples 
in validation phase. The area under curve (AUC) and 
corresponding P values from a Wilcoxon signed rank 
test were performed further. Kaplan-Meier survival curve 
analysis was performed to observe survival rate of miR-
650. Associations between gene expression and OS were 
quantified by HRs and corresponding 95% CIs from Cox 
proportional hazards regression. Data are shown as mean 
± standard deviation. Differences between groups were 
determined by a two-tailed t-test. Statistical analysis was 
performed using MedCalc software.
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